Perspectives to mitigate payer uncertainty in health technology assessment of novel oncology drugs
- Resource Type
- Authors
- Timm Volmer; Lorenzo G. Mantovani; Oriol Solà-Morales
- Source
- Journal of Market Access & Health Policy, Vol 7, Iss 1 (2019)
Journal of Market Access & Health Policy
- Subject
- medicine.medical_specialty
business.industry
Surrogate endpoint
lcsh:Public aspects of medicine
health related quality of life (hrqol)
Health technology
hta
lcsh:RA1-1270
Target population
lcsh:Business
patient access
reimbursement
Editorial
Quality of life (healthcare)
oncology
surrogate endpoint
Medicine
In patient
patient acce
business
Intensive care medicine
Oncology drugs
lcsh:HF5001-6182
Reimbursement
- Language
- English
- ISSN
- 2001-6689
Reimbursement decisions on new oncology drugs are now often made while uncertainty remains about a drug's risk–benefit profile. One consequence of this is a delay in patient access to valuable new medicines. We share our perspectives on strategies to mitigate sources of uncertainty in the health technology assessment process. These include flexible approaches for evaluating the additional benefit, such as better use of surrogate endpoints and health-related quality of life data, and renewed research efforts to define the optimal target population and generate real-world evidence post-authorisation.